The beneficial effect of β-blockers is reported in myocardial infarction (MI). This study compared the effects of propranolol and carvedilol on left-ventricular (LV) volume and function after acute MI. Serial echocardiographic studies were performed on acute MI patients who were treated with primary coronary stenting and medical treatment, including propranolol or carvedilol. Determinants of the changes in LV volume and function were identified by regression analyses. At 6 months, there was no significant difference in change in the LV end-diastolic volume between patients receiving 2 β-blockers. The increase of LV ejection fraction was greater in patients receiving carvedilol. On multivariate analyses, it was found that the kind of β-blocker had no significant influence on the changes in LV volume or ejection fraction, whereas gender and baseline LV ejection fraction were predictive of change in LV ejection fraction. Compared with propranolol, carvedilol did not have a significant benefit on LV remodeling or function after primary coronary stenting in acute MI.
St John Sutton M., Pfeffer MA, Plappert T., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68-75.
2.
Cohn JN, Ferrari R., Sharpe N.Cardiac remodeling- concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
3.
Kopecky SLEffect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol. 2006;98:1115-1119.
4.
Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J., Sharpe N.Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN echo substudy. Circulation. 2004;109:201-206.
5.
Helak JW, Reicheck N.Quantitation of human left ventricular mass and volume by two-dimensional echocardiography: in vivo and anatomic validation. Circulation . 1981;63:1398-1407.
6.
Appleton CP, Galloway JM, Gonzalez MS, Gaballa M., Basnight MAEstimation of left ventricular filling pressure using two-dimensional and Doppler echocardiography in adult patients with cardiac disease: additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol. 1993;22:1972-1982.
7.
Gaudron P., Eilles C., Kugler I., Ertl G.Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanism and early predictors. Circulation. 1993;87:755-763.
8.
Bolognese L. , Neskovic AN, Parodi G., et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002 ;106:2351-2357.
9.
Kloner RA, Rezkalla SHCardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol. 2004;44:276-286.
10.
Freemantle N., Cleland J., Young P., Mason J., Harrison J.β blockade after myocardial infarction: systemic review and meta regression analysis. BMJ. 1999;318:1730-1737.
11.
The CAPRICORN Investigators.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet.2001;357;1385-1390.
12.
Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A.Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation.1997; 96:183-191.
13.
Wei S., Chow LT, Sanderson JEEffect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol. 2000;36:276-281.
14.
Jonsson G., Fossum E., Kjeldsen SE, et al. Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11:377-384.
15.
Jonsson G., Abdelnoor M., Seljeflot I., et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol. 2007;49:27-32.
16.
Feurstein GZ , Hamburger SA, Smith EF, Bril A., Ruffolo RRMyocardial protection with carvedilol. J Cardiovasc Pharmacol. 1992;19:S138-S141.
17.
Yaoita H., Sakabe A., Maehara K., Maruyama Y.Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation. 2002;105:975-980.
18.
Jonsson G., Abdelnoor M., Muller C., Kjeldsen SE, Os I., Westheim A.A comparison of the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction: a single-centre, randomized study of 232 patients. Cardiology. 2005;103:148-155.
19.
Luchner A., Brockel U., Muscholl M., et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res. 2002;53:720-727.
20.
Crabbe DL, Dipla K., Ambati S., et al. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol. 2003;41:300-306.
21.
Cavasin MA, Tao Z., Menson S., Yang XPGender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci. 2004 ;75: 2181-2192.
22.
Murphy E., Steenbergen C.Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res. In press.
